Drug for Age-Related Macular Degeneration Falls Short in Mid-stage Trial

By Reuters Staff

June 25, 2014

(Reuters) - Ohr Pharmaceutical Inc said its experimental eye drop showed no significant benefit over a placebo in reducing the number of injections of another drug directly into the eye, but improved patients' visual clarity.

The drug, Squalamine, is Ohr's lead product and was being tested in a mid-stage trial in patients with age-related macular degeneration (AMD), the leading cause of blindness among the elderly.

An interim analysis of trial data showed patients getting Squalamine needed an average of 6.2 eye injections, while those on placebo needed 6.4.

The main goal was to reduce the number of required injections of Roche Holding AG's Lucentis, which is approved for treating AMD.

However, the study showed that Squalamine improved patients' visual clarity compared to the placebo. Patients getting the drug experienced an average change of about 10.4 letters, compared to 6.3 for those on placebo.

"We believe that showing visual acuity improvements is far more meaningful to a wet AMD patient than reducing the number of injections, especially when the frequency of injections is already low," Brean Capital analyst Jonathan Aschoff wrote in a note.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: